Literature DB >> 6419799

Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V.

C A Fulcher, J E Gardiner, J H Griffin, T S Zimmerman.   

Abstract

Purified human factor VIII procoagulant protein (VIII:C) was treated with purified human activated protein C (APC) and the loss of VIII:C activity correlated with proteolysis of the VIII:C polypeptides. APC proteolyzed all VIII:C polypeptides with mol wt = 92,000 or greater, but not the doublet at mol wt = 79-80,000. These results and our previous thrombin activation studies of purified VIII:C, are analogous with similar studies of factor V and form the basis for the following hypothesis: activated VIII:C consists of heavy and light chain polypeptides [mol wt = 92,000 and mol wt = 79-80,000 (or 71-72,000), respectively] which are similar in Mr to the heavy and light chains of activated factor V. Thrombin activates VIII:C and V by generating these polypeptide chains from larger precursors and APC inactivates both molecules by cleavage at a site located in the heavy chain region of activated VIII:C and V.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6419799

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

Review 1.  Non-tissue factor procoagulants in cancer cells.

Authors:  S G Gordon; M Chelladurai
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

2.  Protein S modulates the anticoagulant action of recombinant human activated protein C: a comparison between neonates and adults.

Authors:  Gerhard Cvirn; Martin Koestenberger; Bettina Leschnik; Christoph Male; Joerg Kutschera; Ulrika Ferstl; Wolfgang Muntean; Guenther Juergens; Siegfried Gallistl
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

3.  Up-regulation of thrombomodulin by activation of histamine H1-receptors in human umbilical-vein endothelial cells in vitro.

Authors:  K Hirokawa; N Aoki
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

Review 4.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

5.  Structural and functional characterization of Factor VIII-delta II, a new recombinant Factor VIII lacking most of the B-domain.

Authors:  N Bihoreau; P Paolantonacci; C Bardelle; M P Fontaine-Aupart; S Krishnan; J Yon; J L Romet-Lemonne
Journal:  Biochem J       Date:  1991-07-01       Impact factor: 3.857

6.  Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa.

Authors:  S W Pipe; R J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

7.  Transcription of thrombomodulin mRNA in mouse hemangioma cells is increased by cycloheximide and thrombin.

Authors:  W A Dittman; T Kumada; P W Majerus
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

8.  Genetic variants associated with protein C levels.

Authors:  C Y Vossen; B P Koeleman; S J Hasstedt; I J Nijman; I J Renkens; P W Callas; F R Rosendaal; E G Bovill
Journal:  J Thromb Haemost       Date:  2013-04       Impact factor: 5.824

Review 9.  Implications of treatment that target protective mechanisms against diabetic nephropathy.

Authors:  Akira Mima; Weier Qi; George L King
Journal:  Semin Nephrol       Date:  2012-09       Impact factor: 5.299

Review 10.  Clinical relevance of protein C.

Authors:  I Pabinger
Journal:  Blut       Date:  1986-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.